Thiazolidinedione derivatives in type 2 diabetes mellitus

Netherlands Journal of Medicine

Volumn 64, Issue 6, 2006, Pages 166-174

  Tack, C J J ^a   Smits, P ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Combination therapy; Monotherapy; Pioglitazone; Rosiglitazone; Thiazolidinedione; Type 2 diabetes mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA TOCOPHEROL; CIGLITAZONE; GEMFIBROZIL; GLIBENCLAMIDE PLUS METFORMIN; GLICLAZIDE; GLIMEPIRIDE; INSULIN; KETOCONAZOLE; METFORMIN; NONSTEROID ANTIINFLAMMATORY AGENT; PIOGLITAZONE; RIFAMPICIN; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; TRIMETHOPRIM; TROGLITAZONE;

BLOOD GLUCOSE MONITORING; BODY WEIGHT DISORDER; CLINICAL TRIAL; DATA ANALYSIS; DIABETIC OBESITY; DRUG ABSORPTION; DRUG APPROVAL; DRUG CHOICE; DRUG CLASSIFICATION; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; EDEMA; FLUID RETENTION; HEART FAILURE; HUMAN; HYPOGLYCEMIA; LIVER DYSFUNCTION; LIVER FAILURE; LIVER TOXICITY; LONG TERM CARE; METABOLIC DISORDER; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; REVIEW; SUBCUTANEOUS FAT; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES;

EID: 33745545448     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (77)

1. Dormandy JA, Charbonnel B, Eckland DJ, et al. PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366:1279-89.
2. Yki-Jarvinen H. The PROactive study: some answers, many questions. Lancet 2005;366:1241-2.
3. Gaede P, Parving HH, Pedersen O. Correspondence: PROactive study. Lancet 2006;367:25-6.
4. Holman RR, Retnakaran R, Farmer A, Stevens R. Correspondence: PROactive study. Lancet 2005;366:1279-89.
5. Fonseca V, Jawa A, Asnani S. Commentary: the PROactive study - the glass is half full. J Clin Endocrinol Metab 2006;91:25-7.
6. Bays H, Mandarino L, DeFronzo RA. Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J Clin Endocrinol Metab 2004;89:463-78.
7. Sohda T, Mizuno K, Imamiya E, Sugiyama Y, Fujita T, Kawamatsu Y. Studies on antidiabetic agents II. Synthesis of 5-[4-(1-methylcyclohexyl-methylmethoxy)-benzyl]thiazalidine-2,4-dione (ADD-3878) and its derivatives. Chem Pharm Bull 1982;30:3580-600.
8. Gale EA. Troglitazone: the lesson that nobody learned? Diabetologia 2006;49:1-6.
9. Semple RK, Chatterjee VK, O'Rahilly S. PPAR gamma and human metabolic disease. J Clin Invest 2006;116:581-9.
10. Natali A, Ferrannini E. Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review. Diabetologia 2006;49:434-41.
11. Kohlroser J, Mathai J, Reichheld J, Banner BF, Bonkovsky HL. Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States Food and Drug Administration. Am J Gastroenterol 2000;95:272-6.
12. Lord JM, Flight IHK, Norman RJ. Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome. The Cochrane Database of Systematic Reviews 2003; issue 2: CD003053.
13. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: From steatosis to cirrhosis. Hepatology 2006;43(S1):S99-112.
14. Scherbaum WA, Goke B. The German pioglitazone study group. Metabolic efficacy and safety of once-daily pioglitazone monotherapy in patients with type 2 diabetes: a double-blind, placebo-controlled study. Horm Metab Res 2002;34:589-95.
15. Herz M, Johns D, Reviriego J, et al. A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia moral antihyperglycemic medication-naive patients with type 2 diabetes mellitus. Clin Ther 2003;25:1074-95.
16. Lebovitz HE, Dole JF, Patwardhan R, Rappaport EB, Freed MI. The Rosiglitazone Clinical Trials study group. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 2001;86:280-8.
17. Philips Ls, Grunberger G, Miller E, Patwardhan R, Rappaport EB, Salzman A. Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. Diabetes Care 2001;24:308-15.
18. Fonseca V, Rosenstock J, Patwardhan R, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus. A randomized controlled trial. JAMA 2000;283:1695-702.
19. Gomez-Perez FJ, Fanghanel-Salmon G, Barbosa JA, et al. Efficacy and safety of rosiglitazone plus metformin in Mexicans with type 2 diabetes. Diabetes Metab Res Rev 2002;18:127-34.
20. Dailey GE 3rd, Noor MA, Park JS, Bruce S, Fiedorek FT. Glycemic control with glyburide/metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: a randomized, double-blind trial. Am J Med 2004;116:223-9.
21. Einhorn D, Rendell M, Rosenzweig J, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. Clin Ther 2000;22:1395-409.
22. Charbonnel BH, Matthews DR, Schernthaner G, Hanefeld M, Brunetti P. The QUARTET Study Group. A long-term comparison of pioglitazone and gliclazide in patients with type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial. Diabet Med 2005;22:399-405.
23. Tan MH, Baksi A, Krahulec B, et al. The GLAL Study Group. Comparison of pioglitazone and gliclazide in sustaining glycemic control over 2 years in patients with type 2 diabetes. Diabetes Care 2005;28:544-50.
24. Matthews DR, Charbonnel BH, Hanefeld M, Brunetti P, Schernthaner G. Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. Diabetes Metab Res Rev 2005;21:167-74.
25. Hallsten K, Virtanen KA, Lonnqvist F, et al. Rosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes. Diabetes 2002;51:3479-85.
26. Tiikkainen M, Hakkinen AM, Korsheninnikova E, Nyman T, Makimattila S, Yki-Jarvinen H. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 2004;53:2169-76.
27. Pavo I, Jermendy G, Varkonyi TT, et al. Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes. J Clin Endocrinol Metab 2003;88:1637-45.
28. Hanefeld M, Brunetti P, Schernthaner GH, Matthews DR, Charbonnel BH. The QUARTET Study Group. One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. Diabetes Care 2004;27:141-7.
29. Nagasaka S, Aiso Y, Yoshizawa K, Ishibashi S. Comparison of pioglitazone and metformin efficacy using homeostasis model assessment. Diabet Med 2004;21:136-41.
30. Charbonnel B, Schernthaner C, Brunetti P, et al. Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. Diabetologia 2005;48:1093-104.
31. Schernthaner G, Matthews DR, Charbonnel B, Hanefeld M, Brunetti P. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. J Clin Endocrinol Metab 2004;89:6068-76.
32. Chiquette E, Ramirez G, DeFronzo R. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med 2004;164:2097-104.
33. Goldberg RB, Kendall DM, Deeg MA, et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005;28:1547-54.
34. Parulkar AA, Pendergrass ML, Granda-Ayala R, Lee TR, Fonseca VA. Nonhypoglycemic effects of thiazolidinediones. Ann Intern Med 2001;134:61-71.
35. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004;351:1106-18.
36. Diamant M, Heine RJ. Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence. Drugs 2003;63:1373-405.
37. Freemantle N. How well does the evidence on pioglitazone back up researchers' claims for a reduction in macrovascular events? BMJ 2005;331:836-8.
38. Wijk JPH van, Koning EJP de, Martens EP, Rabelink TJ. Thiazolidinediones and blood lipids in type 2 diabetes. Arterioscler Thromb Vasc Biol 2003;23:1744-9.
39. Derosa G, Cicero AFG, Gaddi A, et al. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial. Clin Ther 2004;26:744-54.
40. Abbink EJ, de Graaf J, de Haan JH, Heerschap A, Stalenhoef AF, Tack CJ. Effects of pioglitazone in familial combined hyperlipidaemia. J Intern Med 2006;259:107-16.
41. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002;106:679-84.
42. Fullert S, Schneider F, Haak E, et al. Effects of pioglitazone in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study. J Clin Endocrinol Metab 2002;87:5503-6.
43. Rennings AJ, Smits P, Stewart MW, Tack CJ. Fluid retention and vascular effects of rosiglitazone in obese, insulin-resistant, nondiabetic subjects. Diabetes Care 2006;29:581-7.
44. Belcher G, Lambert C, Goh KL, Edwards G, Valbuena M. Cardiovascular effects of treatment of type 2 diabetes with pioglitazone, metformin and glicazide. Int J Clin Pract 2004;58:833-7.
45. Gerstein HC, Yusuf S, Holman R, Bosch J, Pogue J. Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial. Diabetologia 2004;47:1519-27.
46. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes (RECORD): study design and protocol. Diabetologia 2005;jul 16 [Epub ahead of print].
47. Natali A, Baldeweg S, Toschi E, et al. Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes. Diabetes Care 2004;27:1349-57.
48. Pistrosch F, Passauer J, Fischer S, Fuecker K, Hanefeld M, Gross P. In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control. Diabetes Care 2004;27:484-90.
49. Nakamura T, Matsuda T, Kawagoe Y, et al. Effect of pioglitazone on carotid intima-media thickness and arterial stiffness in type 2 diabetic nephropathy patients. Metabolism 2004;53:1382-6.
50. Langenfeld MR, Forst T, Hohberg C, et al. Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study. Circulation 2005;111:2525-31.
51. Charbonnel B, Dormandy J, Erdmann E, Massi-Benedetti M, Skene A; PROactive Study Group. The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients. Diabetes Care 2004;27:1647-53.
52. Chan KA, Truman A, Gurwitz JH, et al. A cohort study of the incidence of serious acute liver injury in diabetic patients treated with hypoglycemic agents. Arch Intern Med 2003;163:728-34.
53. Rajagopalan R, Iyer S, Perez A. Comparison of pioglitazone with other antidiabetic drugs for associated incidence of liver failure: no evidence of increased risk of liver failure with pioglitazone. Diabetes Obes Metab 2005;7:161-9.
54. Hussein Z, Wentworth JM, Nankervis AJ, Proietto J, Colman PG. Effectiveness and side effects of thiazolidinediones for type 2 diabetes: real-life experience from a tertiary hospital. Med J Aust 2004;181:536-9.
55. Marcy TR, Britton ML, Blevins SM. Second-generation thiazolidinediones and hepatotoxicity. Ann Pharmacother 2004;38:1419-23.
56. Farley-Hills E, Sivasankar R, Martin M. Fatal liver failure associated with pioglitazone. BMJ 2004;329:429.
57. Basu A, Jensen MD, McCann F, Mukhopadhyay D, Joyner MJ, Rizza RA. Effects of pioglitazone versus glipizide on body fat distribution, body water content, and hemodynamics in type 2 diabetes. Diabetes Care 2006;29:510-4.
58. Bajaj M, Suraamornkul S, Piper P, et al. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients. J Clin Endocrinol Metab 2004;89:200-6.
59. Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation 2003;108:2941-8.
60. Hruska MW, Amico JA, Langsee Y, et al. The effect of trimethoprim on CYP2C8 mediated rosiglitazone metabolism in human liver microsomes and healthy subjects. Br J Clin Pharmacol 2005;59:70-9.
61. Niemi M, Backman JT, Neuvonen PJ. Effects of trimethoprim and rifampin on the pharmacokinetics of the cytochrome P450 2C8 substrate rosiglitazone. Clin Pharmacol Ther 2004;76:239-49.
62. Park JY, KIM KA, Shin JG, Lee KY. Effect of ketoconazole on the pharmacokinetics of rosiglitazone in healthy subjects. Br J Clin Pharmacol 2004;58:397-402.
63. Park JY, KIM KA, Kang MH, Kim SL, Shin JG. Effect of rifampin on the pharmacokinetics of rosiglitazone in healthy subjects. Clin Pharmacol Ther 2004;75:157-62.
64. Niemi M, Backman JT, Granfors M, Laitila J, Neuvonen M, Neuvonen PJ. Gemfibrozil considerably increases the plasma concentrations of rosiglitazane. Diabetologia 2003;46:1319-23.
65. Jaakola T, Backman JT, Neuvonen M, Neuvonen PJ. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone. Clin Pharmacol Ther 2005;77:404-14.
66. Goudswaard AN, Stalk RP, Valk HW de, Rutten GE. Improving glycaemic control in patients with Type 2 diabetes mellitus without insulin therapy. Diabet Med 2003;20:540-4.
67. Goudswaard AN, Stolk RP, Zuithoff NP, de Valk HW, Rutten GE. Long-term effects of self-management education for patients with Type 2 diabetes taking maximal oral hypoglycaemic therapy: a randomized trial in primary care. Diabet Med 2004;21:491-6.
68. Goudswaard AN, Stolk RP, Zuithoff P, de Valk HW, Rutten GE. Starting insulin in type 2 diabetes: Continue oral hypoglycemic agents? A randomized trial in primary care. J Fam Pract 2004;53:393-9.
69. Viberti G, Kahn SE, Greene DA, et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care 2002;25:1737-43.
70. Bijlage 2 Regeling farmaceutische hulp. Farmacotherapeutisch Kompas 2005:1159.
71. The UKPDS Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:854-65.
72. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999;281:2005-12.
73. Schwartz S, Sievers R, Strange P, Lyness WH, Hollander P. Insulin 70/30 mix plus metformin versus triple oral therapy in the treatment of type 2 diabetes after failure of two oral drugs: efficacy, safety, and cost analysis. Diabetes Care 2003;26:2238-43.
74. Aljabri K, Kozak SE, Thompson DM. Addition of pioglitazone or bedtime insulin to maximal doses of sulfonylurea and metformin in type 2 diabetes patients with poor glucose control: a prospective, randomized trial. Am J Med 2004;116:230.
75. Rosenstock J, Sugimoto D, Strange P, Stewart JA, Soltes-Rak E, Dailey G on behalf of the Insulin Glargine 4014 Study Investigators. Triple Therapy in Type 2 Diabetes: Insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naïve patients. Diabetes Care 2006;29:554-9.
76. Buch HN, Baskar V, Barton DM, Kamalakannan D, Akarca C, Singh BM. Combination of insulin and thiazolidinedione therapy in massively obese patients with Type 2 diabetes. Diabetic Med 2002;19:572.
77. Davidson JA, Perez A, Zhang J; The Pioglitazone 343 Study Group. Addition of pioglitazone to stable insulin therapy in patients with poorly controlled type 2 diabetes: results of a double-blind, multicentre, randomized study. Diabetes Obes Metab 2006;8:164-74.